Table 2.
Bromodomain Inhibitors in Human Clinical Trials
| compound | company | indication | stage/status | ClinicalTrials.gov identifier |
|---|---|---|---|---|
| GSK525762 | GlaxoSmithKline | NUT midline carcinoma and other cancers | phase I (recruiting) | NCT01587703 |
| relapsed, refractory hematologic malignancies | phase I (recruiting) | NCT01943851 | ||
| OTX015 | OncoEthix | acute myeloid leukemia and diffuse large B-cell lymphoma | phase I (recruiting) | NCT01713582 |
| advanced solid tumors | phase IB (recruiting) | NCT02259114 | ||
| acute myeloid leukemia | phase IB/II (withdrawn) | NCT02303782 | ||
| glioblastoma multiforme | phase IIA (ongoing, not recruiting) | NCT02296476 | ||
| CPI-0610 | Constellation Pharmaceuticals | progressive lymphoma | phase I (recruiting) | NCT02296476 |
| multiple myeloma | phase I (recruiting) | NCT02157636 | ||
| acute leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasms | phase I (recruiting) | NCT02158858 | ||
| TEN-010 | Tensha | acute myeloid leukemia and myelodysplastic therapeutics syndrome | phase I (recruiting) | NCT02308761 |
| solid tumors | phase I (recruiting) | NCT01987362 | ||
| RVX-208 | Resverlogix Corp. | dyslipidemia, atherosclerosis, acute coronary syndrome, cardiovascular disease | phase II (completed) | NCT00768274 |
| atherosclerosis and coronary artery disease | phase II (completed) | NCT01058018 | ||
| coronary artery disease | phase II (completed) | NCT01067820 | ||
| coronary artery disease and dyslipidemia | phase II (completed) | NCT01423188 | ||
| diabetes | phase II (completed) | NCT01728467 | ||
| dyslipidemia and coronary artery disease | phase II (terminated) | NCT01863225 |